pretickt

Is VTRS a good stock to buy?

Viatris Inc. · end-of-day data as of Nov 13, 2026

Viatris
VTRS · $23.87B
$20.82+0.7%
Nov 13, 2026 · close
$16$18$20SepOctNov9:3016:003 months +29.7%Nov 13 · close
▲ 6
  • ConsensusBuy · 12
  • FCF yield+8.6%
  • Trendbullish
  • MAs4 of 4
  • MACD0.17
  • Sector▲ +15.9%
Neutral
  • Earnings in104d
  • Support-13.5%
  • Off 52w high-1.8%
  • Volume0.7x
  • Bollingerupper half
  • News0.00
  • PT$21.00 +0.9%
  • 52w range$10–$21
  • ATR+2.7%
  • Off ATH-72.9%
  • InsidersNone in 90d
▼ 1
  • RSI70

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Viatris a good stock to buy?

Viatris is strong on 1 of the 5 questions about the business; weak on demand, economics and fragility. With a loss over the last 12 months, Viatris has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand shrinking
  2. Advantage some edge
  3. Economics losing money
  4. Execution delivers
  5. Fragility fragile
  6. Price like its peers
DemandDo people want more of what it sells?shrinking

VTRS sales growth revenue growth

-4%a year, for the last 3 years

Viatris' sales fell 4% a year for 3 years, to $14.3B in fiscal 2025.

VTRS analysts' forecast revenue estimates

+4%the sales they expect next fiscal year, on the last

Analysts expect Viatris' sales to grow 4% to $14.8B in fiscal 2026 (7 analysts).

VTRS peers

pretickt analysis+4%its sales in 12 months, on a year before

Viatris' sales grew 4% in the 12 months to Sep 30, 2026, faster than Zoetis (+1%), slower than Alnylam (+56%), Incyte (+25%) and Steris (+8%).

VTRS sales by business revenue by segment

64%of its sales from Brands

Brands brought Viatris 64% of its sales in fiscal 2025; Generics 36%.

Advantage moatIs it hard to copy?some edge

VTRS return on capital ROIC

pretickt analysis0%earned before tax on the money invested in it

Viatris earned 0% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Zoetis 163%, Alnylam 31%, Incyte 29% and Steris 17%.

VTRS margin on each sale gross margin

35%left after making the product

Viatris kept 35% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 74%.

EconomicsDoes it make good money?losing money

VTRS margin after costs profit margin

-1%of sales left after running the business

Viatris' operating margin was -1% in the 12 months to Sep 30, 2026, against 10% in fiscal 2022.

ExecutionDoes it deliver what it promises?delivers

VTRS earnings vs estimates

7 of 8quarters above the analysts' estimate

Viatris beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Nov 5, 2026.

VTRS insider selling

-$1.09Msold, net, by its executives in 12 months

Viatris' executives and directors sold a net $1.09M of shares in the 12 months to Nov 13, 2026; none bought.

VTRS number of employees

-6%fewer people in a year

Viatris had 30,000 employees at the end of fiscal 2025, 6% fewer than a year before.

VTRS CEO pay

$15.27Mfor fiscal 2025, 66% of it in stock and options

Viatris paid its CEO $15.27M for fiscal 2025, 66% of it in stock and options.

Fragility risksCould something break it?fragile

VTRS financial health Altman Z-score

1.2Altman Z-score, safe above 3

Viatris' Altman Z-score is 1.2 (Nov 13, 2026), below 1.8, the distress zone.

VTRS quality checks Piotroski score

6 of 9checks passed

Viatris passes 6 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on profit, long-term debt and gross margin.

VTRS biggest customers

11%of sales from its biggest customer

Cencora made 11% of Viatris' sales in fiscal 2025.

VTRS shareholders institutional ownership

pretickt analysis
  • Vanguard11.2% ▲
  • Fidelity8.3% ▲
  • BlackRock7.4% ▲
1,068institutions hold it; the largest added shares

1,068 institutions hold 92% of Viatris' shares (Jun 30, 2026); Vanguard, Fidelity and BlackRock added shares that quarter.

VTRS in past recessions

pretickt analysis-1%its sales in the worst one

Viatris' sales fell in 1 of the last 2 US recessions, by as much as 1% in fiscal 2009.

Price valuationIs the price reasonable?like its peers

VTRS price vs profit P/E ratio

—it lost money in 12 months: no P/E

Viatris has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

VTRS price vs assets price to book

1.7×times what its assets are worth on paper

Viatris trades at 1.7 times its book value (Nov 13, 2026); its peers' median is 5.3.

VTRS analysts' target price target

+1%to their average target

Analysts' average price target for Viatris is $21.00, 1% above the Nov 13, 2026 close of $20.82.

What is Viatris' P/E ratio?

Viatris has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Viatris trades at 1.7 times its book value (Nov 13, 2026); its peers' median is 5.3.

Is Viatris profitable?

Viatris' operating margin was -1% in the 12 months to Sep 30, 2026, against 10% in fiscal 2022.

Are insiders selling Viatris stock?

Viatris' executives and directors sold a net $1.09M of shares in the 12 months to Nov 13, 2026; none bought.

How does Viatris make money?

Brands brought Viatris 64% of its sales in fiscal 2025; Generics 36%.

Who owns Viatris stock?

1,068 institutions hold 92% of Viatris' shares (Jun 30, 2026); Vanguard, Fidelity and BlackRock added shares that quarter.

How many employees does Viatris have?

Viatris had 30,000 employees at the end of fiscal 2025, 6% fewer than a year before.

Who are Viatris' biggest customers?

Cencora made 11% of Viatris' sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.